| Name | Title | Contact Details |
|---|---|---|
Olivier Loeillot |
President and Chief Commercial Officer | Profile |
Travis Harkness |
Vice President Supply Chain and Analytics | Profile |
Travis Ward |
Director of R&D | Profile |
Derek Carroll |
Director of R&D | Profile |
Christine Gebski |
Vice President, Product Management and Field Applications | Profile |
CIMA Labs Inc. develops and manufactures orally disintegrating tablet and enhanced-absorption oral drug delivery systems. The Company's lead, orally disintegrating tablet technologies, OraSolv and DuraSolv, allow an active drug ingredient, which is
Amyloid diseases are a diverse group of disorders, characterized by the deposition of amyloid protein fibrils in vital organs and tissues. There are approximately 30 different types of amyloidosis, each resulting from the misfolding and aggregation of a specific protein, and they are all severely debilitating, progressive, and often fatal.
Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
Woodcock Washburn is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.